Fintech▲ 60

Immix Biopharma completes trial enrollment, eyes milestones

Globenewswire·March 30, 2026 at 12:45 PM

Immix Biopharma has successfully completed enrollment for its BLA-enabling NEXICART-2 trial, focusing on relapsed/refractory AL amyloidosis. This milestone, achieved as per prior guidance, brings the company closer to key regulatory submissions. Topline results for the trial are anticipated in Q3 2026, paving the way for a subsequent Biologics License Application (BLA) submission. This progress marks a critical step in the development of their therapeutic candidate, signaling potential advancements in treating this specific patient population.

Immix Biopharma completes trial enrollment, eyes milestones

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing